Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Other Working Capital Changes (2017 - 2025)

Spero Therapeutics (SPRO) has disclosed Other Working Capital Changes for 10 consecutive years, with $670000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Other Working Capital Changes rose 2492.86% year-over-year to $670000.0, compared with a TTM value of -$2.0 million through Sep 2025, down 461.78%, and an annual FY2024 reading of -$2.3 million, down 383.73% over the prior year.
  • Other Working Capital Changes was $670000.0 for Q3 2025 at Spero Therapeutics, up from -$319000.0 in the prior quarter.
  • Across five years, Other Working Capital Changes topped out at $5.0 million in Q2 2023 and bottomed at -$6.2 million in Q3 2022.
  • Average Other Working Capital Changes over 5 years is -$380263.2, with a median of -$195000.0 recorded in 2021.
  • The sharpest move saw Other Working Capital Changes plummeted 343.18% in 2021, then skyrocketed 2492.86% in 2025.
  • Year by year, Other Working Capital Changes stood at $2.3 million in 2021, then decreased by 16.14% to $1.9 million in 2022, then crashed by 55.9% to $834000.0 in 2023, then crashed by 338.01% to -$2.0 million in 2024, then skyrocketed by 133.75% to $670000.0 in 2025.
  • Business Quant data shows Other Working Capital Changes for SPRO at $670000.0 in Q3 2025, -$319000.0 in Q2 2025, and -$363000.0 in Q1 2025.